Skip to main content

Arguments Over GDD Lawsuit Centralization on September 27

Arguments Over GDD Lawsuit Centralization on September 27

Arguments Over GDD Lawsuit Centralization on September 27

Introduction

The U.S. Judicial Panel on Multidistrict Litigation (JPML)  will consider oral arguments on whether to consolidate all Gadolinium Deposition Disease (GDD) lawsuits filed against the manufacturers of MRI contrast dyes for coordinated pretrial proceedings.

In a motion filed in July, plaintiffs' lawyers requested all gadolinium complaints pending in the federal court system be centralized in the Northern District of California. Each of the MRI contrast dye manufacturers has filed a response opposing the centralization process citing that there are too few plaintiffs’ law firms involved in the cases and too many different manufacturers to form a multidistrict litigation (MDL). Bayer Healthcare filed a supplemental response on September 20 in support of the motion and outlining arguments to be made during the upcoming hearing. The U.S. JPML  is set to hear oral arguments on the motions from several plaintiffs and manufacturers on September 27, at the Phillip Burton U.S. Courthouse in San Francisco.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!